Annual EBITDA
-$24.17 M
-$39.34 M-259.28%
31 December 2023
Summary:
Arcturus Therapeutics Holdings annual earnings before interest, taxes, depreciation & amortization is currently -$24.17 million, with the most recent change of -$39.34 million (-259.28%) on 31 December 2023. During the last 3 years, it has risen by +$46.27 million (+65.69%). ARCT annual EBITDA is now -259.28% below its all-time high of $15.17 million, reached on 31 December 2022.ARCT EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$9.82 M
+$6.63 M+40.30%
30 September 2024
Summary:
Arcturus Therapeutics Holdings quarterly earnings before interest, taxes, depreciation & amortization is currently -$9.82 million, with the most recent change of +$6.63 million (+40.30%) on 30 September 2024. Over the past year, it has increased by +$8.66 million (+46.85%). ARCT quarterly EBITDA is now -108.19% below its all-time high of $119.98 million, reached on 31 December 2022.ARCT Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$18.20 M
+$8.66 M+32.24%
30 September 2024
Summary:
Arcturus Therapeutics Holdings TTM earnings before interest, taxes, depreciation & amortization is currently -$18.20 million, with the most recent change of +$8.66 million (+32.24%) on 30 September 2024. Over the past year, it has dropped by -$120.64 million (-117.77%). ARCT TTM EBITDA is now -115.48% below its all-time high of $117.58 million, reached on 31 March 2023.ARCT TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ARCT EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -259.3% | +46.9% | -117.8% |
| 3 y3 years | +65.7% | +81.5% | +90.6% |
| 5 y5 years | -15.0% | -39.4% | -25.4% |
ARCT EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -259.3% | +88.0% | -108.2% | +81.5% | -115.5% | +91.0% |
| 5 y | 5 years | -259.3% | +88.0% | -108.2% | +82.3% | -115.5% | +91.0% |
| alltime | all time | -259.3% | +88.0% | -108.2% | +82.3% | -115.5% | +91.0% |
Arcturus Therapeutics Holdings EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$9.82 M(-40.3%) | -$18.20 M(-32.2%) |
| June 2024 | - | -$16.46 M(-35.6%) | -$26.86 M(-56.4%) |
| Mar 2024 | - | -$25.55 M(-176.0%) | -$61.64 M(-483.4%) |
| Dec 2023 | -$24.17 M(-259.3%) | $33.63 M(-281.9%) | $16.08 M(-84.3%) |
| Sept 2023 | - | -$18.49 M(-63.9%) | $102.44 M(+18.0%) |
| June 2023 | - | -$51.24 M(-198.2%) | $86.84 M(-26.1%) |
| Mar 2023 | - | $52.18 M(-56.5%) | $117.58 M(+675.0%) |
| Dec 2022 | $15.17 M(-107.5%) | $119.98 M(-452.0%) | $15.17 M(-110.5%) |
| Sept 2022 | - | -$34.08 M(+66.3%) | -$144.31 M(-11.6%) |
| June 2022 | - | -$20.50 M(-59.2%) | -$163.31 M(-16.8%) |
| Mar 2022 | - | -$50.23 M(+27.2%) | -$196.39 M(-2.6%) |
| Dec 2021 | -$201.66 M(+186.3%) | -$39.50 M(-25.6%) | -$201.66 M(+4.6%) |
| Sept 2021 | - | -$53.08 M(-0.9%) | -$192.81 M(+20.3%) |
| June 2021 | - | -$53.58 M(-3.4%) | -$160.32 M(+37.5%) |
| Mar 2021 | - | -$55.49 M(+81.1%) | -$116.59 M(+65.5%) |
| Dec 2020 | -$70.44 M(+188.0%) | -$30.64 M(+48.8%) | -$70.44 M(+39.8%) |
| Sept 2020 | - | -$20.59 M(+109.0%) | -$50.39 M(+36.8%) |
| June 2020 | - | -$9.86 M(+5.5%) | -$36.84 M(+35.0%) |
| Mar 2020 | - | -$9.34 M(-11.8%) | -$27.29 M(+11.6%) |
| Dec 2019 | -$24.45 M(+16.3%) | -$10.60 M(+50.4%) | -$24.45 M(+68.4%) |
| Sept 2019 | - | -$7.05 M(+2233.1%) | -$14.52 M(+24.4%) |
| June 2019 | - | -$302.00 K(-95.4%) | -$11.67 M(-45.3%) |
| Mar 2019 | - | -$6.51 M(+886.2%) | -$21.34 M(+0.2%) |
| Dec 2018 | -$21.02 M | -$660.00 K(-84.3%) | -$21.29 M(-17.3%) |
| Sept 2018 | - | -$4.20 M(-57.9%) | -$25.75 M(+4.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2018 | - | -$9.97 M(+54.4%) | -$24.62 M(+56.8%) |
| Mar 2018 | - | -$6.46 M(+26.2%) | -$15.70 M(+22.2%) |
| Dec 2017 | -$10.34 M(+992.0%) | -$5.12 M(+66.6%) | -$12.85 M(-224.2%) |
| Sept 2017 | - | -$3.07 M(+192.3%) | $10.35 M(+87.8%) |
| June 2017 | - | -$1.05 M(-70.9%) | $5.51 M(+735.8%) |
| Mar 2017 | - | -$3.61 M(-120.0%) | $659.00 K(-169.6%) |
| Dec 2016 | -$947.00 K(-35.0%) | $18.08 M(-328.6%) | -$947.00 K(-83.7%) |
| Sept 2016 | - | -$7.91 M(+34.1%) | -$5.80 M(+164.1%) |
| June 2016 | - | -$5.90 M(+13.1%) | -$2.19 M(+50.7%) |
| Mar 2016 | - | -$5.22 M(-139.4%) | -$1.46 M(-0.1%) |
| Dec 2015 | -$1.46 M(-95.6%) | $13.23 M(-407.2%) | -$1.46 M(-93.1%) |
| Sept 2015 | - | -$4.31 M(-16.6%) | -$21.28 M(-22.8%) |
| June 2015 | - | -$5.16 M(-1.1%) | -$27.55 M(-8.8%) |
| Mar 2015 | - | -$5.22 M(-20.8%) | -$30.21 M(-8.0%) |
| Dec 2014 | -$32.82 M(+219.6%) | -$6.59 M(-37.7%) | -$32.82 M(+3.0%) |
| Sept 2014 | - | -$10.58 M(+35.2%) | -$31.86 M(+30.5%) |
| June 2014 | - | -$7.82 M(-0.1%) | -$24.41 M(+37.3%) |
| Mar 2014 | - | -$7.83 M(+39.2%) | -$17.78 M(+73.2%) |
| Dec 2013 | -$10.27 M(+588.2%) | -$5.63 M(+79.5%) | -$10.27 M(+110.1%) |
| Sept 2013 | - | -$3.13 M(+162.6%) | -$4.89 M(+142.6%) |
| June 2013 | - | -$1.19 M(+281.5%) | -$2.02 M(+61.5%) |
| Mar 2013 | - | -$313.00 K(+27.2%) | -$1.25 M(+33.5%) |
| Dec 2012 | -$1.49 M(-61.5%) | -$246.00 K(-6.1%) | -$935.00 K(+35.7%) |
| Sept 2012 | - | -$262.00 K(-38.6%) | -$689.00 K(+61.4%) |
| June 2012 | - | -$427.00 K | -$427.00 K |
| Dec 2011 | -$3.88 M | - | - |
FAQ
- What is Arcturus Therapeutics Holdings annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Arcturus Therapeutics Holdings?
- What is Arcturus Therapeutics Holdings annual EBITDA year-on-year change?
- What is Arcturus Therapeutics Holdings quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Arcturus Therapeutics Holdings?
- What is Arcturus Therapeutics Holdings quarterly EBITDA year-on-year change?
- What is Arcturus Therapeutics Holdings TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Arcturus Therapeutics Holdings?
- What is Arcturus Therapeutics Holdings TTM EBITDA year-on-year change?
What is Arcturus Therapeutics Holdings annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of ARCT is -$24.17 M
What is the all time high annual EBITDA for Arcturus Therapeutics Holdings?
Arcturus Therapeutics Holdings all-time high annual earnings before interest, taxes, depreciation & amortization is $15.17 M
What is Arcturus Therapeutics Holdings annual EBITDA year-on-year change?
Over the past year, ARCT annual earnings before interest, taxes, depreciation & amortization has changed by -$39.34 M (-259.28%)
What is Arcturus Therapeutics Holdings quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of ARCT is -$9.82 M
What is the all time high quarterly EBITDA for Arcturus Therapeutics Holdings?
Arcturus Therapeutics Holdings all-time high quarterly earnings before interest, taxes, depreciation & amortization is $119.98 M
What is Arcturus Therapeutics Holdings quarterly EBITDA year-on-year change?
Over the past year, ARCT quarterly earnings before interest, taxes, depreciation & amortization has changed by +$8.66 M (+46.85%)
What is Arcturus Therapeutics Holdings TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of ARCT is -$18.20 M
What is the all time high TTM EBITDA for Arcturus Therapeutics Holdings?
Arcturus Therapeutics Holdings all-time high TTM earnings before interest, taxes, depreciation & amortization is $117.58 M
What is Arcturus Therapeutics Holdings TTM EBITDA year-on-year change?
Over the past year, ARCT TTM earnings before interest, taxes, depreciation & amortization has changed by -$120.64 M (-117.77%)